Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial

The increased risks of death and adverse events with erythropoiesis-stimulating agent (ESA) therapy targeting a higher hemoglobin level are established. It is uncertain whether the adverse effects of ESA therapy are related to dose and are mitigated when a fixed low ESA dose is used. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saglimbene, Valeria, Palmer, Suetonia C., Craig, Jonathan C., Ruospo, Marinella, Nicolucci, Antonio, Tonelli, Marcello, Johnson, David, Lucisano, Giuseppe, Williams, Gabrielle, Valentini, Miriam, D’Alonzo, Daniela, Pellegrini, Fabio, Strippoli, Paolo, Salomone, Mario, Santoro, Antonio, Maffei, Stefano, Hegbrant, Jörgen, Tognoni, Gianni, Strippoli, Giovanni F. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332066/
https://www.ncbi.nlm.nih.gov/pubmed/28249030
http://dx.doi.org/10.1371/journal.pone.0172735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332066/
https://www.ncbi.nlm.nih.gov/pubmed/28249030
http://dx.doi.org/10.1371/journal.pone.0172735

Ejemplares similares